This week, please join author Mathew S. Maurer as he discusses the article "Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial." For the episode transcript, visit: <span style= "font-size: 12.0pt; font-family: 'Lato',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Aptos; mso-ligatures: standardcontextual; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"> <a href= "https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ahajournals.org%2Fdo%2F10.1161%2Fpodcast.20260126.13097&data=05%7C02%7Caidan.derrico%40wolterskluwer.com%7C260b547d92104e2c72d508de5d17a30c%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C639050553417208715%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=SqBxghy0LGmxm8DEARKi3yfm4azGB8143iTjzuXefS8%3D&reserved=0"> https://www.ahajournals.org/do/10.1161/podcast.20260126.13097</a>

Circulation January 13, 2026 Issue

Each 15-minute podcast begins with an overview of the issue's contents and main take-home messages for busy clinicians on the run. This is followed by a deep dive into a featured article of particular clinical significance: views will be heard from both author and editor teams for a "behind the scenes" look at the publication. Expect a fun, highly conversational and clinically-focused session each week!